CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-26 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,700 | 175,308 | ||
| 2026-06-25 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +1,400 | $2.59 | $4K | 57,850 |
| 2026-06-25 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +900 | $8.05 | $7K | 58,750 |
| 2026-06-25 | Lesage Anne Chief Early Development | Sale 10b5-1 | −2,300 | $35.12 | $81K | 56,450 |
| 2026-06-25 | Lesage Anne Chief Early Development | Sale 10b5-1 | −2,300 | $35.12 | $81K | 131,669 |
| 2026-06-25 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −900 | 74,100 | ||
| 2026-06-25 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,400 | 7,072 | ||
| 2026-06-25 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +15,000 | $2.59 | $39K | 80,631 |
| 2026-06-25 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −11,600 | $34.45 | $400K | 69,031 |
| 2026-06-25 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −3,400 | $35.09 | $119K | 65,631 |
| 2026-06-25 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 190,008 | ||
| 2026-06-18 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +300 | $2.59 | $777 | 65,931 |
| 2026-06-18 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −300 | $34.00 | $10K | 65,631 |
| 2026-06-18 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −300 | 205,008 | ||
| 2026-06-15 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −2,191 | $31.05 | $68K | 135,309 |
| 2026-06-15 | Modig Berndt Chief Executive Officer | Sale 10b5-1 | −100 | $31.46 | $3K | 135,209 |
| 2026-06-12 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −117 | $32.20 | $4K | 65,631 |
| 2026-06-11 | Lu Peng Chief Medical Officer | Shares withheld for taxes | −109 | $31.51 | $3K | 65,748 |
| 2026-06-04 | Nijdam Anna Principal Accounting Officer | Sale | −2,670 | $30.87 | $82K | 46,275 |
| 2026-05-22 | Nijdam Anna Principal Accounting Officer | Option exercise | +5,501 | $20.00 | $110K | 54,446 |
Page 5 of 9 · 170 trades